Sugi Predict

Sugi Predict / Compounds / SCHEMBL561399

SCHEMBL561399

SCHEMBL561399

FC(F)(F)c1ccc2c(c1)N(CCCCl)c1ccccc1S2

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.75
▸ MAPT P10636 7/20 0.75
▸ NPSR1 Q6W5P4 5/20 0.75
▸ SMN1; SMN2 Q16637 5/20 0.75
▸ MEN1 O00255 4/20 0.75
▸ KMT2A Q03164 4/20 0.75
▸ TDP1 Q9NUW8 4/20 0.75
▸ USP2 O75604 4/20 0.75
▸ KDM4E B2RXH2 2/20 0.75
▸ HPGD P15428 1/20 0.75
▸ ALOX12 P18054 1/20 0.75
▸ TP53 P04637 5/20 0.72
▸ MAPK1 P28482 5/20 0.72
▸ CYP1A2 P05177 3/20 0.72
▸ ABCB1 P08183 3/20 0.72
▸ HTR1A P08908 3/20 0.72
▸ ADRA2A P08913 3/20 0.72
▸ ADORA3 P0DMS8 3/20 0.72
▸ CYP2D6 P10635 3/20 0.72
▸ CHRM1 P11229 3/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL561173 0.96 LMNA (0.73) LMNAMAPTNPSR1SMN1; SMN2MEN1
SCHEMBL26002991 0.90 LMNA (0.62) LMNAMAPTNPSR1SMN1; SMN2MEN1
SCHEMBL8218991 0.87 LMNA (0.98) LMNAMAPTNPSR1SMN1; SMN2MEN1
SCHEMBL14724203 0.87 TP53 (0.72) LMNAMAPTNPSR1SMN1; SMN2MEN1
SCHEMBL14809956 0.87 TP53 (0.72) LMNAMAPTNPSR1SMN1; SMN2MEN1
SCHEMBL24439717 0.87 FPR2 (0.78) LMNAMAPTNPSR1SMN1; SMN2MEN1
SCHEMBL7746782 0.85 FPR2 (0.69) LMNAMAPTNPSR1SMN1; SMN2MEN1
SCHEMBL24224669 0.84 TP53 (0.71) LMNAMAPTNPSR1SMN1; SMN2MEN1
Triflupromazine SCHEMBL32668886 0.84 CYP1A2 (1.00) LMNAMAPTNPSR1SMN1; SMN2MEN1
SCHEMBL23059754 0.84 TP53 (0.71) LMNAMAPTNPSR1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034193-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2025-01-30 — — US disclosed
US-12145963-B2 Phenothiazine derivatives and uses thereof CAMP4 THERAPEUTICS CORPORATION (US) 2024-11-19 — — US disclosed
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2023-08-17 — — US disclosed
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2023-08-17 — — US disclosed
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2023-08-17 — — US disclosed
US-11542290-B2 Phenothiazine derivatives and uses thereof CAMP4 THERAPEUTICS CORPORATION (US) 2023-01-03 — — US disclosed
US-11542290-B2 Phenothiazine derivatives and uses thereof CAMP4 THERAPEUTICS CORPORATION (US) 2023-01-03 — — US disclosed
US-20210061837-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2021-03-04 — — US disclosed
US-20210061837-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2021-03-04 — — US disclosed
WO-2019195789-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION (US) 2019-10-10 — — WO disclosed
WO-2008021745-A2 HEPATITIS C VIRUS ENTRY INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2008-02-21 — — WO disclosed
EP-0620813-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II BRITISH BIO-TECHNOLOGY LIMITED (GB) 1994-10-26 — — EP disclosed
EP-0414422-B1 2-Oxo-1-oxa-8-azaspiro [4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof RICHTER GEDEON VEGYESZET (HU) 1994-04-06 — — EP disclosed
WO-1993014069-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-07-22 — — WO disclosed
US-5157038-A Antidepressants; tranquilizers; treatment of schizophrenia and epilepsy; antilepmic agents RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1992-10-20 — — US disclosed
EP-0414422-A2 2-Oxo-1-oxa-8-azaspiro [4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 1991-02-27 — — EP disclosed
US-4183926-A NEUROLEPTIC ACTIVITY SOCIETE D'ETUDES DE PRODUITS CHIMIQUES (FR) 1980-01-15 — — US disclosed
US-4139632-A Psychotropic 2-trifluoromethyl-10-[3-(3-hydroxy-pyrrolidino)-propyl]-phenothiazine compounds EISAI CO., LTD. (JP) 1979-02-13 — — US disclosed
US-4018922-A NEUROLEPTICS, ANALGESICS, SPASMOLYTICS, AND ANTIHISTAMINES ROUSSEL-UCLAF (FR) 1977-04-19 — — US disclosed
US-3988453-A Novel phenothiazines as neuroleptics ROUSSEL-UCLAF (FR) 1976-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061837-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF RPLP2, RPS2, RPLP1 LMNA 546/4885MAPT 651/4885NPSR1 4043/4885
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF RPLP2, RPS2, RPLP1 LMNA 546/4885MAPT 651/4885NPSR1 4043/4885
US-12145963-B2 Phenothiazine derivatives and uses thereof RPLP2, RPS2, RPLP1 LMNA 546/4885MAPT 651/4885NPSR1 4043/4885
US-20250034193-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF RPLP2, RPS2, RPLP1 LMNA 546/4885MAPT 651/4885NPSR1 4043/4885
US-11542290-B2 Phenothiazine derivatives and uses thereof RPLP2, RPS2, RPLP1 LMNA 546/4885MAPT 651/4885NPSR1 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.